Merck may appeal to Supreme Court after again losing fight to protect Cubicin patents

Eric Palmer

& Co. is running low on options a federal appeals Thursday declined to back four that would have held at bay for 5 more years generics of the antibiotic , the drug that was key to its $ 9.5 billion buyout of Cubist. Next up may be an to the U.S. Court.

FiercePharma News

Share This Post

Related Articles

Leave a Reply

© 2019 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS